Maintenance venetoclax plus subcutaneous cytarabine for fit adults with AML

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, randomized, open-label phase III study enrolls fit adults aged 18–60 with acute myeloid leukemia who achieved complete remission after first- or second-line chemotherapy but are not eligible for immediate bone marrow transplantation. Participants receive maintenance venetoclax together with subcutaneous cytarabine as a bridge to transplant or when transplantation is delayed or cancelled. The primary outcome is disease-free survival, with follow-up for relapse and safety endpoints. The trial is conducted at Sohag University sites in Sohag, Egypt.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age : 18 - 60 years . Patients who are not eligible for immediate bone marrow transplantation. Newly diagnosed AML patients who attained CR after 1st line. Refractory / recurrant AML patients who attained CR after 2nd line .

Exclusion Criteria:

* Patients not on CR . Age : younger than 18 or older than 60 . Patients not eligible for bone marrow transplation

Where it's running

• Sohag university hospital
  Sohag, Egypt Recruiting
• Sohag university
  Sohag, Egypt Recruiting

Study contacts

• Study coordinator: Eman I Abdelshakour, Asst lect
• Email: Eman011065@med.sohag.edu.eg
• Phone: +201063901450

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Longitudinal multi-center molecular biomarker registry for blood cancers

  This registry will collect serial blood samples and leftover tissue from people with AML or follicular lymphoma to see if molecular biomarkers predict disease course and treatment outcomes.

  Recruiting at 13 sites Tempus AI · Iowa City, Iowa and 12 other locations · NCT07154823

• Targeting measurable residual AML with tagraxofusp plus azacitidine and venetoclax

  This trial tests whether adding tagraxofusp to azacitidine and venetoclax can safely help control measurable residual acute myeloid leukemia (AML) in adults who are in remission but still have detectable disease.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07148180

• Efficacy of HMAs vs Intensive Chemotherapy in AML Guided by 5hmC MRD

  This trial tests whether a blood 5hmC biomarker can guide choosing between hypomethylating agents or intensive chemotherapy for adults with newly diagnosed AML.

  Recruiting Phase 2 The Methodist Hospital Research Institute · Houston, Texas · NCT07060001

• High-dose irradiation followed by immunotherapy for high-risk leukemia patients

  This study is testing a new treatment that combines high-dose radiation with special immune cells to see if it helps patients with high-risk leukemia do better after a stem cell transplant.

  Recruiting University Of Perugia · Perugia, PG · NCT06845592

• L-Annamycin and Cytarabine for treating relapsed AML

  This study is testing if a new combination of L-Annamycin and Cytarabine can help adults with relapsed Acute Myeloid Leukaemia feel better when other treatments haven't worked.

  Recruiting at 28 sites Phase 2/3 Moleculin Biotech, Inc. · Birmingham, Alabama and 27 other locations · NCT06788756

• AMX-883 in AML and high-risk MDS: a first-in-class dosing study

  This early-stage study tests AMX-883 alone and with another drug to see if it is safe and shows early signs of benefit in people with AML or high-risk MDS.

  Recruiting at 3 sites Phase 1 Amphista Therapeutics Ltd · New York, New York and 2 other locations · NCT07723703

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.